TC Biopharm (Holdings) Plc (TCBPW)
- Previous Close
0.0117 - Open
0.0160 - Bid --
- Ask --
- Day's Range
0.0113 - 0.0199 - 52 Week Range
0.0113 - 0.0199 - Volume
50,341 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7540 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
tcbiopharm.comRecent News: TCBPW
Compare To: TCBPW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TCBPW
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-108.91%
Return on Equity (ttm)
-556.68%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.59M
Diluted EPS (ttm)
-0.7540
Balance Sheet and Cash Flow
Total Cash (mrq)
980.96k
Total Debt/Equity (mrq)
159.94%
Levered Free Cash Flow (ttm)
-6.85M
Research Analysis: TCBPW
Company Insights: TCBPW
TCBPW does not have Company Insights